Research Article

Effect of new beta-adrenergic blocking agent, Atenolol (Tenormin), on pain frequency, trinitrin consumption, and exercise ability.

Br Med J 1975; 3 doi: https://doi.org/10.1136/bmj.3.5977.195 (Published 26 July 1975) Cite this as: Br Med J 1975;3:195
  1. P Roy,
  2. L Day,
  3. E Sowton

    Abstract

    In 11 patients with severe angina pectoris a new beta-blocking drug, atenolol (Tenormin; I.C.I.66082), was found in a double-blind randomized trial to reduce significantly the frequency of anginal attacks (P less than 0-001) and the amount of trinitrin consumed (P less than 0-03) in comparison with practolol and placebo. There was no significant improvement in the patients' ability to exercise on the bicycle ergometer.